AAD: Benzoyl Peroxide/Clindamycin Gel Effective for Rosacea
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




AAD: Benzoyl Peroxide/Clindamycin Gel Effective for Rosacea

By Alison Palkhivala

SAN FRANCISCO, CA -- March 25, 2003 -- A topical gel consisting of benzoyl peroxide 5% and clindamycin 1% is effective for treatment of moderate rosacea, according to results of a double-blind, multicentre study.

D. Breneman, MD, from University Dermatology Consultants, Cincinnati, Ohio, United States, and colleagues randomised 53 adults with stage II rosacea to treatment with a combination topical agent containing 5% benzoyl peroxide and 1% clindamycin or a placebo gel for 12 weeks. The findings were presented in a poster here on March 23rd at the 61st Annual Meeting of the American Academy of Dermatology.

The study included patients who had between eight and 50 papules or pustules on the face, no more than two nodules and Overall Rosacea Severity Assessment (ORSA) scores of at least 2.5. Patients with concomitant acne vulgaris or seborrhea dermatitis were excluded from the study.

By Week 6, patients using the combination gel achieved an average reduction in papules and pustules from baseline of over 70%. These reductions were maintained to the end of the 12-week trial and were significantly superior to placebo (P</=0.02).

Patients treated with the combination gel also experienced significant improvements in symptoms of rosacea, compared with baseline scores and compared with placebo (P</=0.01 for both). Patients taking the combination gel had approximately 30% improvement in ORSA score compared with 10% in those taking the placebo. Patients' impressions of improvement were also higher among those who used the active agent versus the placebo group.

No serious adverse events occurred in either group. The most common side effects seen in patients taking the combination gel but not the placebo were burning and itching at the application site.

Based on these findings, the authors concluded that the 5% benzoyl peroxide and 1% clindamycin combination gel is superior to placebo for the treatment of moderate rosacea and is well tolerated.

The study was sponsored by Dermik Laboratories.

[Study title: Double Blind, Multicenter, Comparison Study of Combination Benzoyl Peroxide/clindamycin or Placebo in Patients with Moderate Rosacea. Abstract p43]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities